Skip to main content
Top
Published in: Virology Journal 1/2018

Open Access 01-12-2018 | Research

HPV genotype determination and E6/E7 mRNA detection for management of HPV positive women

Authors: Maria Teresa Bruno, Martina Ferrara, Valentina Fava, Agnese Rapisarda, Angela Coco

Published in: Virology Journal | Issue 1/2018

Login to get access

Abstract

Background

Clinical management of HPV positive women is difficult since many of the infections, including high-risk oncogene genotypes (hr-HPV), are transient. Therefore only a limited number of patients have a high-grade lesion and sending all HPV positive women for colposcopy would only increase costs and unnecessary treatment, with serious psychological consequences for patients. The need has emerged to identify other HPV related markers able to correctly detect women with a high-risk of developing high-grade lesions. Genotyping and the search for E6/E7 mRNA are among the possible candidates.

Methods

The study was carried out by means of an observational analysis of the data relative to 674 HR-HPV positive women who we had observed from January 2013 to June 2015; the data had been gathered in a database at the HPV Center of the University Hospital of Catania, Italy.
Women were considered eligible for this study if the following data was present in the database: Pap TEST, histologic evaluation, HPV TEST and E6/E7 mRNA detection.
We calculated the Odds Ratio (OR) of woman who were mRNA positive, with CIN2+ lesions, and Odds Ratio of HPV16 positive women.

Results

Transcripts were detected in 23.6% (69/292) of the women with CIN1 and in 97.2% (210/220) of those with CIN2 + .
Regarding genotyping, the 81,8% (180/220) of the women with CIN2+ had genotype 16, while only 18.1% (40/220) had genotype 18, 31, 33, 45.
We calculated the OR in the group of HPV16 women with CIN2+ (OR = 4.62; 95% CI = 3.13 to 6.82), this value increased (OR = 106.12; 95% CI = 53.71 to 209.69) in women with CIN2+ and positive mRNA.

Discussion

The presence of the HPV16 genotype in our study was associated with a risk 5 times greater of developing a high-grade lesion (CIN2+) (OR = 4.62 95% CI:3.13–6.82); this supports the hypothesis that it would be opportune to have targeted protocols for the management of HPV 16 positive women. The results showed that there was an association between E6/E7 mRNA expression and histology (OR = 106.12; 95% CI = 53.71 to 209.69). The E6/E7 mRNA test showed a higher prevalence of E6 and E7 transcripts in patients with higher-grade lesions.

Conclusion

The results of this study suggest that the HPV genotype determination and E6/E7 mRNA detection would find an important application for management of HPV positive women.
Literature
1.
go back to reference Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs IO, Sottaceti C, Sasieni P. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362:1871–6.CrossRefPubMed Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs IO, Sottaceti C, Sasieni P. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362:1871–6.CrossRefPubMed
2.
go back to reference Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–101.CrossRefPubMed Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–101.CrossRefPubMed
3.
go back to reference Ronco G, Biggeri A, Confortini M, Rossi PG, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M. HPV DNA based primary screening for cervical cancer precursors Epidemiologia & Prevenzione. Epidemiol Prev. 2012;36:1–72. Ronco G, Biggeri A, Confortini M, Rossi PG, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M. HPV DNA based primary screening for cervical cancer precursors Epidemiologia & Prevenzione. Epidemiol Prev. 2012;36:1–72.
4.
go back to reference Muñoz N, Bosch FX, Castellsagué X, Díaz M, De Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278–85.CrossRefPubMed Muñoz N, Bosch FX, Castellsagué X, Díaz M, De Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278–85.CrossRefPubMed
5.
go back to reference Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam S, Cain J, Garcia FA, Moriarty A, Waxman A, Wilbur D, Wentzensen N, Downs L, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the prevention and early detection of cervical Cancer. CA Cancer J Clin. 2012;62:147–72.CrossRefPubMedPubMedCentral Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam S, Cain J, Garcia FA, Moriarty A, Waxman A, Wilbur D, Wentzensen N, Downs L, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the prevention and early detection of cervical Cancer. CA Cancer J Clin. 2012;62:147–72.CrossRefPubMedPubMedCentral
6.
go back to reference Sjoeborg KD, Trope A, Lie AK, Jonassen CM, Steinbakk M, Hansen M, Jacobsen MB, Cuschieri K, Eskild A. HPV genotype distribution according to severity of cervical neoplasia. Gynecol Oncol. 2010;118:29–34.CrossRefPubMed Sjoeborg KD, Trope A, Lie AK, Jonassen CM, Steinbakk M, Hansen M, Jacobsen MB, Cuschieri K, Eskild A. HPV genotype distribution according to severity of cervical neoplasia. Gynecol Oncol. 2010;118:29–34.CrossRefPubMed
7.
go back to reference García-Espinosa B, Moro-Rodríguez E, Alvarez-Fernández E. Genotype distribution of human papillomavirus (HPV) in histological sections of cervical intraepithelial neoplasia and invasive cervical carcinoma in Madrid, Spain. BMC Cancer. 2012;12:533.CrossRefPubMedPubMedCentral García-Espinosa B, Moro-Rodríguez E, Alvarez-Fernández E. Genotype distribution of human papillomavirus (HPV) in histological sections of cervical intraepithelial neoplasia and invasive cervical carcinoma in Madrid, Spain. BMC Cancer. 2012;12:533.CrossRefPubMedPubMedCentral
8.
go back to reference Peitsaro P, Johansson B, Syrjänen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol. 2002;40:886–91.CrossRefPubMedPubMedCentral Peitsaro P, Johansson B, Syrjänen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol. 2002;40:886–91.CrossRefPubMedPubMedCentral
9.
go back to reference Zhang D, Zhang Q, Zhou L, Huo L, Zhang Y, Shen Z, Zhu Y. Comparison of prevalence, viral load, physical status and expression of human papillomavirus-16, −18 and −58 in esophageal and cervical cancer: a case-control study. BMC Cancer. 2010;10:650.CrossRefPubMedPubMedCentral Zhang D, Zhang Q, Zhou L, Huo L, Zhang Y, Shen Z, Zhu Y. Comparison of prevalence, viral load, physical status and expression of human papillomavirus-16, −18 and −58 in esophageal and cervical cancer: a case-control study. BMC Cancer. 2010;10:650.CrossRefPubMedPubMedCentral
10.
go back to reference Saunier M, Monnier-Benoit S, Mauny F, Dalstein V, Briolat J, Riethmuller D, Kantelip B, Schwarz E, Mougin C, Pretet JL. Analysis of human papillomavirus type 16 (HPV16) DNA load and physical state for identification of HPV16-infected women with high-grade lesions or cervical carcinoma. J Clin Microbiol. 2008;46:3678–85.CrossRefPubMedPubMedCentral Saunier M, Monnier-Benoit S, Mauny F, Dalstein V, Briolat J, Riethmuller D, Kantelip B, Schwarz E, Mougin C, Pretet JL. Analysis of human papillomavirus type 16 (HPV16) DNA load and physical state for identification of HPV16-infected women with high-grade lesions or cervical carcinoma. J Clin Microbiol. 2008;46:3678–85.CrossRefPubMedPubMedCentral
11.
go back to reference Cheung LK, Cheung TH, Ng CWY, Yu MY, Wong MCS, Siu SSN, Yim SF, Chan PKS. Analysis of human papillomavirus type 18 load and integration status from low-grade cervical lesion to invasive cervical Cancer. J Clin Microbiol 2009; 47: 287–293. Cheung LK, Cheung TH, Ng CWY, Yu MY, Wong MCS, Siu SSN, Yim SF, Chan PKS. Analysis of human papillomavirus type 18 load and integration status from low-grade cervical lesion to invasive cervical Cancer. J Clin Microbiol 2009; 47: 287–293.
12.
go back to reference Azizi N, Brazete J, Hankins C, Soldi D, Fontaine J, Koushik A, Rachlis A, Pourreaux K, Ferenczy A, Franco E, Coutlée F. Canadian Women’s HIV study group. Influence of human papillomavirus type 16 (HPV-16) E2 polymorphism on quantification of HPV-16 episomal and integrated DNA in cervicovaginal lavages from women with cervical intraepithelial neoplasia. J Gen Virol. 2008;89:1716–28.CrossRefPubMed Azizi N, Brazete J, Hankins C, Soldi D, Fontaine J, Koushik A, Rachlis A, Pourreaux K, Ferenczy A, Franco E, Coutlée F. Canadian Women’s HIV study group. Influence of human papillomavirus type 16 (HPV-16) E2 polymorphism on quantification of HPV-16 episomal and integrated DNA in cervicovaginal lavages from women with cervical intraepithelial neoplasia. J Gen Virol. 2008;89:1716–28.CrossRefPubMed
13.
go back to reference Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Rapace M, Raab S, Sherman M, Wilbur D, Wright T Jr, Giovani N. Forum Group Members, Bethesda 2001 Workshop. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114–9.CrossRefPubMed Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Rapace M, Raab S, Sherman M, Wilbur D, Wright T Jr, Giovani N. Forum Group Members, Bethesda 2001 Workshop. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114–9.CrossRefPubMed
14.
go back to reference Corden SA, Sant-Cassia LJ, Easton AJ, Morris AG. The integration of HPV-18 DNA in cervical carcinoma. J Clin Pathol Mol Pathol. 1999;52:275–82.CrossRef Corden SA, Sant-Cassia LJ, Easton AJ, Morris AG. The integration of HPV-18 DNA in cervical carcinoma. J Clin Pathol Mol Pathol. 1999;52:275–82.CrossRef
16.
go back to reference Clad A, Reuschenbach M, Weinschenk J, Grote R, Rahmsdorf J, Freudenberg N. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with hybrid capture 2 and cytology. J Clin Microbiol. 2011;49:1071–6.CrossRefPubMedPubMedCentral Clad A, Reuschenbach M, Weinschenk J, Grote R, Rahmsdorf J, Freudenberg N. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with hybrid capture 2 and cytology. J Clin Microbiol. 2011;49:1071–6.CrossRefPubMedPubMedCentral
17.
go back to reference Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, Gadag V, Holloway G, Bartellas E, Kum N, Giede C, Lear A. Aptima HPV E6/E7 mRNA Test Is as sensitive as hybrid capture 2 assay but more specific at detecting cervical Precancer and Cancer. J Clin Microbiol. 2011;49:557–64.CrossRefPubMedPubMedCentral Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, Gadag V, Holloway G, Bartellas E, Kum N, Giede C, Lear A. Aptima HPV E6/E7 mRNA Test Is as sensitive as hybrid capture 2 assay but more specific at detecting cervical Precancer and Cancer. J Clin Microbiol. 2011;49:557–64.CrossRefPubMedPubMedCentral
18.
go back to reference Varnai AD, Bollmann M, Bankfalvi A, Speich N, Schmitt C, Griefingholt H, Kovács K, Klozoris C, Bollmann R. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol Rep. 2008;19:457–65.PubMed Varnai AD, Bollmann M, Bankfalvi A, Speich N, Schmitt C, Griefingholt H, Kovács K, Klozoris C, Bollmann R. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol Rep. 2008;19:457–65.PubMed
19.
go back to reference Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence implications for cervical disease progression and monitoring. J Med Virol. 2004;73:65–70.CrossRefPubMed Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence implications for cervical disease progression and monitoring. J Med Virol. 2004;73:65–70.CrossRefPubMed
20.
go back to reference Molden T, Kraus T, Karlsen F, Skomedal H, Nygard JF, Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4, 136 women 30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomark Prev. 2005;14:367–72.CrossRef Molden T, Kraus T, Karlsen F, Skomedal H, Nygard JF, Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4, 136 women 30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomark Prev. 2005;14:367–72.CrossRef
21.
go back to reference Burger EA, Kornør H, Klemp M, Lauvrak V, Kristiansen IS. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol. 2011;120:430–8.CrossRefPubMed Burger EA, Kornør H, Klemp M, Lauvrak V, Kristiansen IS. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol. 2011;120:430–8.CrossRefPubMed
22.
go back to reference Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schincaglia P, Zorzi M, Confortini M, Cuzick J. New technologies for cervical cancer screening working group the new Technologies for Cervical Cancer screening (NTCC) working group. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomized controlled trial. Lancet Oncol. 2006;7:547–55.CrossRefPubMed Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schincaglia P, Zorzi M, Confortini M, Cuzick J. New technologies for cervical cancer screening working group the new Technologies for Cervical Cancer screening (NTCC) working group. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomized controlled trial. Lancet Oncol. 2006;7:547–55.CrossRefPubMed
23.
go back to reference Benevolo M, Terrenato I, Mottolese M, Marandino F, Carosi M, Rollo F, Ronchetti L, Muti P, Mariani L, Sindico S, Vocaturo G, Vocaturo A. Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological of HC2-positive patients. Cancer Causes Control. 2011;22:869–75.CrossRefPubMed Benevolo M, Terrenato I, Mottolese M, Marandino F, Carosi M, Rollo F, Ronchetti L, Muti P, Mariani L, Sindico S, Vocaturo G, Vocaturo A. Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological of HC2-positive patients. Cancer Causes Control. 2011;22:869–75.CrossRefPubMed
24.
go back to reference Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N. New technologies for cervical cancer screening working group. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100:492–50.CrossRefPubMed Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N. New technologies for cervical cancer screening working group. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100:492–50.CrossRefPubMed
25.
go back to reference Moscicki AB, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, Shiboski S. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol. 2010;116:1373–80.CrossRefPubMedPubMedCentral Moscicki AB, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, Shiboski S. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol. 2010;116:1373–80.CrossRefPubMedPubMedCentral
26.
go back to reference Cattani P, Zannoni GF, Ricci C, D'Onghia S, Trivellizzi IN, Di Franco A, Vellone VG, Durante M, Fadda G, Scambia G, Capelli G, De Vincenzo R. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol. 2009;47:3895–901.CrossRefPubMedPubMedCentral Cattani P, Zannoni GF, Ricci C, D'Onghia S, Trivellizzi IN, Di Franco A, Vellone VG, Durante M, Fadda G, Scambia G, Capelli G, De Vincenzo R. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol. 2009;47:3895–901.CrossRefPubMedPubMedCentral
27.
go back to reference Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW. 2012 updated consensus guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Lower Genital Tract Dis. 2013;17:1–27.CrossRef Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW. 2012 updated consensus guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Lower Genital Tract Dis. 2013;17:1–27.CrossRef
28.
go back to reference Sørbye SW, Fismen S, Gutteberg TJ, Mortensen ES, Skjeldestad FE. HPV mRNA is more specific than HPV DNA in triage of women with minor cervical lesions. PLoSOne. 2014;9:e112934.CrossRef Sørbye SW, Fismen S, Gutteberg TJ, Mortensen ES, Skjeldestad FE. HPV mRNA is more specific than HPV DNA in triage of women with minor cervical lesions. PLoSOne. 2014;9:e112934.CrossRef
Metadata
Title
HPV genotype determination and E6/E7 mRNA detection for management of HPV positive women
Authors
Maria Teresa Bruno
Martina Ferrara
Valentina Fava
Agnese Rapisarda
Angela Coco
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2018
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-018-0957-z

Other articles of this Issue 1/2018

Virology Journal 1/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.